The Caspase 2 pipeline drugs market research report outlays comprehensive information on the Caspase 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Caspase 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Ophthalmology, Central Nervous System, Gastrointestinal, and Immunology which include the indications Open-Angle Glaucoma, Non-Arteritic Anterior Ischemic Optic Neuropathy, Unspecified Central Nervous System Disorders, Hypoxic-Ischemic Encephalopathy, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, and Inflammation. It also reviews key players involved in Caspase 2 targeted therapeutics development with respective active and dormant or discontinued products.
The Caspase 2 pipeline targets constitutes close to five molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase I, Preclinical, and Discovery stages are 1, 1, 1, and 2 respectively.
Caspase 2 overview
Caspase-2, also known as CASP2, is an enzyme involved in the activation cascade of caspases, which are responsible for executing the process of apoptosis, or programmed cell death. Caspase-2 plays a critical role in the regulation of apoptosis by either activating proteins necessary for cell death or inactivating proteins that promote cell survival. Caspase-2 associates with other proteins, such as PIDD1 and CRADD, to form a complex called the PIDDosome. This complex is essential for activating caspase-2 and triggering apoptosis in response to genotoxic stress, which can result from DNA damage.
For a complete picture of Caspase 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
